Roche Investigates Alzheimer's Delaying Drug; Industry Sees Major Moves

Major health news includes Roche's plan to test a drug for Alzheimer's, a US data-sharing initiative in healthcare, Nordic Capital's acquisition bid for Bavarian Nordic, and an increase in Novo Nordisk's Wegovy prescriptions post-U.S. ban on copycats. These developments mark significant strides in the health sector.

Swiss pharmaceutical giant Roche Holding has unveiled plans to conduct a clinical trial to determine if its experimental drug, Trontinemab, can delay or prevent Alzheimer's disease in at-risk individuals. This move is a significant part of Roche's expansive efforts to combat cognitive decline, a growing concern globally.

Meanwhile, the Trump administration is gearing up to boost data interoperability in healthcare. A meeting scheduled at the White House will bring together health officials, including Health and Human Services Secretary Robert F. Kennedy Jr., and tech giant executives, aiming at improved data sharing across the sector, Bloomberg News reports.

In other industry movements, the vaccine maker Bavarian Nordic has become the center of a $3 billion acquisition bid by Nordic Capital and Permira. Additionally, Novo Nordisk's weight-loss drug, Wegovy, has shown promising sales growth following a US ban on its imitation versions, marking a pivotal moment for the company to prove its market potential.

(With inputs from agencies.)